PRECIGEN, INC. Payments to Acquire Other Productive Assets
PRECIGEN, INC. (PGEN) reported Payments to Acquire Other Productive Assets of $0 for the 6-month period ending 2018-06-30, per its 10-Q filed 2018-08-13.
Discontinued › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquireOtherProductiveAssets · last filed 2018-08-13
- PRECIGEN, INC. payments to acquire other productive assets for fiscal 2017 was $14.22M, a 96.29% increase from fiscal 2016.
- PRECIGEN, INC. payments to acquire other productive assets for fiscal 2016 was $7.24M.
- PRECIGEN, INC. payments to acquire other productive assets for fiscal 2015 was $0.00.
- PRECIGEN, INC. payments to acquire other productive assets for fiscal 2014 was $0.00.
| Period end | Payments to Acquire Other Productive Assets 6 month | Payments to Acquire Other Productive Assets 12 month |
|---|---|---|
| 2018-06-30 | $0.00 10-Q · filed 2018-08-13 | |
| 2017-12-31 | $14.22M 10-K · filed 2018-03-01 | |
| 2017-06-30 | $14.22M 10-Q · filed 2018-08-13 | |
| 2016-12-31 | $7.24M 10-K · filed 2018-03-01 | |
| 2015-12-31 | $0.00 10-K · filed 2018-03-01 | |
| 2014-12-31 | $0.00 10-K · filed 2017-03-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NewAmsterdam Pharma Co N.V. (NAMS) | $2.719B | -15.37 | |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |